JARID2 inhibition reprograms human hematopoietic progenitor cells to enhance bone marrow transplantation
- 25 September 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6474-6488
Abstract
Hematopoietic stem cell (HSC) transplantation is a common treatment for many blood disorders and can be a lifesaving therapy for patients with leukemias, lymphomas, and multiple myeloma. Umbilical cord blood (UCB) serves as a valuable source of hematopoietic stem and progenitor cells (HSPCs) for transplantation, particularly for patients lacking a matched donor. However, the limited number of repopulating cells in UCB units restricts its clinical utility. Our prior studies showed that the genetic deletion of the polycomb repressive complex 2 (PRC2) cofactor Jarid2 in mouse multipotent progenitors (MPPs) conveyed ectopic self-renewal capacity. Here, we hypothesized that the function of human HSPCs could be enhanced through JARID2 inhibition. In this study, we demonstrate that both constitutive and transient knockdown (KD) of JARID2 increases the number and enhances the functionality of human HSPCs both in vitro and in vivo. This phenotype was distinct from the inhibition of EZH2 in UCB cells, suggesting that the mechanism was independent of the PRC2 cofactor activity of JARID2. Mechanistically, JARID2 KD promotes a quiescent, long-term self-renewal gene expression program governed by STAT1 upregulation and characterized by an MHC class II immunophenotype. Analogous to mice, these mechanisms conferred HSC-like potential to human MPPs in vivo. Taken together, these findings highlight JARID2 inhibition as a novel and reversible approach to expand functional UCB-derived HSPCs ex vivo, potentially improving access to stem cell transplantation for a wider patient population.Keywords
This publication has 44 references indexed in Scilit:
- Single-Unit versus Double-Unit Umbilical Cord Blood Transplantation in Children and Young Adults with Residual Leukemic DiseaseTransplantation and Cellular Therapy, 2019
- JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor CellsCancer Cell, 2018
- Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic MalignanciesClinics in Chest Medicine, 2017
- Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2015
- An Optimized microRNA Backbone for Effective Single-Copy RNAiCell Reports, 2013
- Clinical significance of genetic aberrations in secondary acute myeloid leukemiaAmerican Journal of Hematology, 2012
- Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignanciesAmerican Journal of Hematology, 2011
- Availability of Cord Blood Extends Allogeneic Hematopoietic Stem Cell Transplant Access to Racial and Ethnic MinoritiesTransplantation and Cellular Therapy, 2010
- A high-throughput chemical genetic screen in zebrafish establishes that prostaglandin E2 is a potent regulator of hematopoietic stem cell formationBlood Cells, Molecules, and Diseases, 2007
- Comparison of Hematopoietic Activities of Human Bone Marrow and Umbilical Cord Blood CD34 Positive and Negative CellsStem Cells, 1999